The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients

December 9, 2010 7:33 am | by Bio-Medicine.Org | News | Comments

EAST HANOVER, N.J., Dec. 9, 2010 /- A new study shows that the addition of everolimus (Afinitor® tablets) to the hormonal therapy tamoxifen in patients with hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer who have been...


Anthera Announces Update Call Regarding Vial Problems

December 9, 2010 7:32 am | by Bio-Medicine.Org | News | Comments

HAYWARD, Calif., Dec. 9, 2010 /- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH ), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it will hold a conference call to provide an update on the ongoing investigation and...


HeartWare plans to sell $100M in senior notes

December 9, 2010 6:45 am | by The Associated Press | News | Comments

Heart device maker HeartWare International Inc. said Thursday it plans to sell $100 million in senior notes due in 2016, and disclosed that its biggest shareholder is selling part of its stake in the company.The news sent shares sliding $6.04, or 6.8 percent, to $82.86 in morning...


Innovative Micro Technology adds to its arsenal of through-silicon via offerings

December 9, 2010 6:33 am | by I-Micronews | News | Comments

Innovative Micro Technology, Inc. (IMT) announced the addition of a new geometry point in its technology roadmap for Through Silicon Vias (TSVs).

MicroVision and Pioneer to jointly commercialize innovative laser display products

December 9, 2010 6:32 am | by I-Micronews | News | Comments

MicroVision, Inc. (NASDAQ: MVIS), a leader in innovative ultra-miniature laser display technology, announced today that it has entered into a memorandum of understanding (MOU) with Pioneer Corporation, one of the top original equipment manufacturers (OEMs) of high-performance audio, video...

Alnylam elects Fanucci to board

December 9, 2010 5:36 am | by Mass High Tech: The Journal of New England Technology | News | Comments

RNAi-focused therapeutics firm Alnylam Pharmaceuticals Inc. has elected Marsha H. Fanucci, former chief financial officer of fellow Cambridge-based biotechnology company Millennium Pharmaceuticals Inc., to its board of directors.

Alere gets OK for $50M stock buyback

December 9, 2010 5:35 am | by Mass High Tech: The Journal of New England Technology | News | Comments

The board of directors at Waltham-based Alere Inc., the healthcare management company formerly known as Inverness Medical Innovations, has given it approval of a stock repurchase program for up to $50 million worth of its common or preferred stock.

Manufacturing Growth Forecasted for 2011

December 9, 2010 5:35 am | by Material Handling Industry of America | News | Comments

The U.S. manufacturing sector will grow in 2011, with manufacturing revenue increasing by 5.6% according to the Institute for Supply Management (ISM) semi-annual forecast released.The overall forecast projects optimism about the U.S. economy for 2011.


VirtuoSaph® Plus Endoscopic Vessel Harvesting System from Terumo Continues the Advancement of the Minimally Invasive Technique for Coronary and Peripheral Artery Bypass Graft...

December 9, 2010 5:35 am | by Bio-Medicine.Org | News | Comments

ANN ARBOR, Mich., Dec. 9, 2010 /- Terumo Cardiovascular Systems has announced the introduction of the VirtuoSaph® Plus Endoscopic Vessel Harvesting System following clearance by the U.S. Food and Drug Administration (FDA). (Logo:


Osseon® Therapeutics Names Gary Coughlen, CPA as New Chief Financial Officer

December 9, 2010 5:34 am | by Bio-Medicine.Org | News | Comments

SANTA ROSA, Calif., Dec. 9, 2010 /- Osseon Therapeutics, Inc. today named Mr. Gary Coughlen, CPA as the company's Chief Financial Officer, effective immediately. Mr. Coughlen was most recently the Chief Financial Officer of PolyRemedy, Inc., a private-equity medical device company focused...


Aromatase Inhibitors Increased Risk of Heart Disease in Postmenopausal Women with Breast Cancer

December 9, 2010 5:34 am | by AACR | News | Comments

SAN ANTONIO - Postmenopausal women who take aromatase inhibitors as a treatment for breast cancer may be at an increased risk for developing cardiovascular disease, according to the results of a meta-analysis.


Obese Women with ER-positive/HER2-negative Breast Cancer Have Poorer Survival Rates

December 9, 2010 5:34 am | by AACR | News | Comments

SAN ANTONIO - Obesity was associated with worse overall and disease-free survival in women with operable breast cancer treated with adjuvant chemotherapy, but for the first time, researchers observed this finding in only a specific subset of patients – those with estrogen receptor...


Estrogen Alone is Effective for Reducing Breast Cancer Risk

December 9, 2010 5:34 am | by AACR | News | Comments

SAN ANTONIO - While endogenous estrogen (i.e., estrogen produced by ovaries and by other tissues) does have a well-known carcinogenic impact, hormone replacement therapy (HRT) utilizing estrogen alone (the exogenous estrogen) provides a protective effect in reducing breast cancer risk,...


PROTECT II Interim Results Demonstrate That Impella Is Not Superior to the Intra-Aortic Balloon Pump in Reducing Major Adverse Events in High Risk Patients Receiving Percutane...

December 9, 2010 5:33 am | by Bio-Medicine.Org | News | Comments

MAHWAH, N.J., Dec. 9, 2010 /- MAQUET Cardiovascular, the leading distributor of intra-aortic balloon pumps (IABP) worldwide, learned that the PROTECT II clinical trial, sponsored by Abiomed, that compared the safety and effectiveness of the Impella percutaneous ventricular assist device...


HeartWare International, Inc. Announces Concurrent Public Offerings of Convertible Senior Notes and Common Stock

December 9, 2010 5:33 am | by Bio-Medicine.Org | News | Comments

FRAMINGHAM, Mass. and SYDNEY, Dec. 9, 2010 /- HeartWare International, Inc. (Nasdaq: HTWR, ASX: HIN) ("HeartWare") announced today its intention to offer, subject to market and other conditions, $100 million principal amount of convertible senior notes due 2017 (the "notes") pursuant to...



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.